China Biologic Products, headquartered in Beijing, is a leading plasma products manufacturer in China listed on the NASDAQ under the ticker CBPO. The company collects human plasma from a dozen plasma stations across China and manufactures human albumin, intravenous immunoglobulin, specialty immunoglobulin, and human coagulation factor VIII. These products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening and immune-deficiency diseases.
Warburg Pincus invested in CBPO through a series of share purchases from existing shareholders and the open market from 2010 to 2013.
Back to Previous Page